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Abstract 
FBXO11 is a member of the F-box protein family, 
which is characterized by an approximately 40 
amino acid motif, named the F-box domain. It is the 
substrate binding subunit of the SKP1-CUL1-F-box 
(SCF) ubiquitin ligase complex. FBXO11 is 
conserved from nematodes to mammals, and both 
human FBXO11 and its worm ortholog (DRE-1) 
form functional SCF ubiquitin ligase complexes. By 
binding to and mediating the degradation of its 
substrate proteins, FBXO11 plays important roles in 
regulating cell cycle regulation, tumorigenesis, and 
tumor cell metastasis. The gene encoding FBXO11 
was found to be deleted or mutated in various types 
of human tumors. 
Keywords: F-box, ubiquitin, cell cycle, 
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Identity 
Other names: FBX11, PRMT9, UBR6, VIT1 
HGNC (Hugo): FBXO11 
Location: 2p16.3 
DNA/RNA 
Description 
The gene is encoded by 23 exons that are located on 
chrosome 2p16.3 (NM_025133.4). The first ATG 
occurs in exon 2. There is an alternatively spliced 
transcript variant encoding an isoform in which the 
first ATG occurs in exon 1 (NM_001190274). 
Transcription 
3.8 kb mRNA; 2532 bp open reading frame (for 
NM_025133.4). 4 kb mRNA; 2784 bp open reading 
frame (for NM_001190274). 
Protein 
Description 
The fbxo11 gene encodes the FBXO11 protein 
which has 843 amino acids (NP_079409.3), with an 
estimated molecular weight of 94 kDa. The protein 
contains from N-term to C-term, an F-box domain, 
three CASH domains (domain present in 
carbohydrate binding proteins and sugar 
hydrolyses), and a Zinc finger domain. Other splice 
variants were reported (Cook et al., 2006). 
Expression 
Widely expressed. 
Localisation 
Mainly nuclear. 
Function 
Substrate recognition component of the SCFFBXO11 
ubiquitin ligase complex consisting of CUL1, 
RBX1, SKP1 and FBXO11. Known interactors 
include p53, BCL6, CDT2, Blimp and Snail (Figure 
2). 
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Figure 1. 
FBXO11 functions in lymphomagenesis 
The SCFFBXO11 complex mediates ubiquitylation and 
degradation of BCL6, a transcription repressor that 
is required for normal germinal center development. 
Constitutive expression of BCL6 occurs in at least 
70% patients with diffuse large B-cell lymphoma 
(DLBCL). The gene encoding FBXO11 was found 
to be deleted or mutated in multiple DLBCL cell 
lines, and this inactivation of FBXO11 correlated 
with increased levels and stability of BCL6 (Duan et 
al., 2012). Moreover, FBXO11 is deleted or mutated 
in 12-15% of primary DLBCL. 
Fbxo11 in cell cycle regulation 
FBXO11 interacts with CDT2 (a DCAF protein that 
controls cell-cycle progression) and recruits CDT2 
to the SCFFBXO11 complex to promote its proteasomal 
degradation (Abbas et al., 2013; Rossi et al., 2013). 
CDK-mediated phosphorylation of Thr464 present 
in the CDT2 degron inhibits recognition by FBXO11 
(Rossi et al., 2013). Inhibition of SCFFBXO11-
mediated CDT2 degradation result in a delay in cell-
cycle exit in response to serum deprivation or TGFβ 
treatment. The functional interaction between 
FBXO11 and CDT2 is evolutionary conserved from 
worms to humans and plays an important role in 
regulating the timing of cell-cycle exit. 
FBXO11 in TGFβ signaling pathway 
FBXO11 was implicated in the TGFβ signaling 
pathway. Mice with inactivated FBXO11 exhibited 
significant phospho-Smad2 (P-Smad2) nuclear 
staining in the epithelial cells of palatal shelves, 
eyelids, and airways of the lung, potentially leading 
to the developmental defects of these tissues 
(Tateossian et al., 2009). 
SCFFBXO11-mediated degradation of CDT2 was 
shown to contribute to the stabilization of the 
CRL4CDT2 substrate p21 and Set8 in response to 
serum withdraw and TGFβ stimulation (Abbas et al., 
2013; Rossi et al., 2013). Depletion of FBXO11 was 
shown also to inhibit lung adenocarcinoma 
eptithelial cells migration (Abbas et al., 2013). 
FBXO11 in the regulation of cell metastasis 
FBXO11 was shown to mediate the ubiquitylation 
and degradation of SNAIL (Zheng et al., 2014), a 
transcription factor that promotes epithelial-
mesenchymal transition (EMT). The recognition of 
SNAIL by FBXO11 appears to be dependent on Ser-
11 phosphorylation of SNAIL by protein kinase D1 
(PDK1). FBXO11 blocks SNAIL-induced EMT, 
tumor initiation, and metastasis in multiple breast 
cancer models. 
DRE-1/FBXO11 in C. elegans development 
The C. elegans ortholog of FBXO11 is DRE-1, 
whose mutant phenotypes include precocious 
terminal differentiation of epidermal stem cells and 
altered temporal patterning of gonadal outgrowth 
(Fielenbach et al., 2007). DRE-1 forms a functional 
SCF ubiquitin ligase, and was reported to target the 
conserved transcription factor BLMP-1 for 
proteasomal degradation (Horn et al., 2014). The 
DRE-1 - BLMP-1 axis was important for regulating 
developmental timing within the heterochronic 
circuit during late larval development. blmp-1 
deletion was shown to suppress dre-1 mutant 
phenotypes and exhibit developmental timing 
defects opposite to dre-1. 
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Figure 2. 
Other functions 
FBXO11 has been shown to act as an adaptor protein 
to mediate the neddylation of p53, which leads to the 
suppression of p53 transcriptional activity. 
SCFFBXO11 does not mediate the ubiquitylation of 
p53 (Abida et al., 2007). 
Homology 
Human FBXO11 is highly conserved in evolution 
that shares 100% amino acid identity with Pan 
troglodytes, 99.8% identity with Canis lupus 
familiaris, 99.5% identity with Mus musculus, and 
61% identity with C. elegans. 
Mutations 
Somatic 
FBXO11-inactivating mutations contribute to the 
pathogenesis of diffuse large B cell lymphoma 
(DLBCL) through stabilization of BCL6 (Duan et 
al., 2012).  
FBXO11 mutations were also identified in other 
human cancers, such as colon, lung, ovary, and head 
and neck tumors (Kan et al., 2010; Lohr et al., 2012; 
Stransky et al., 2011; Yoshida et al., 2011).  
In mice, a homozygous mutation of Fbxo11 results 
in cleft palate defects, facial clefting, and perinatal 
lethality.  
Moreover, haploinsufficient mutant alleles cause 
otitis media, a disorder that affects approximately 
15% of children (Hardisty-Hughes et al., 2006). 
Implicated in 
Diffuse large B-cell lymphoma 
Note 
FBXO11-inactivating mutations are found in human 
diffuse large B cell lymphoma (DLBCL), suggesting 
that FBXO11 may function as a tumor suppressor 
whose loss of function contributes to the 
pathogenesis of DLBCL through stabilization of 
BCL6. 
Disease 
Diffuse Large B-cell lymphoma. 
Otitis Media 
Note 
Genetic studies show a correlation between 
particular SNP variants of FBXO11 and the 
development of chronic otitis media (Segade et al., 
2006). 
Disease 
Otitis media, inflammation of the middle ear, is the 
most common cause of hearing impairment in 
children. 
Vitiligo 
Note 
By comparing RNA isolated from vitiligo 
melanocyte cultures versus control cultures, VIT1 
was found to be downregulated in vitiligo 
melanocytes, suggesting that it might be associated 
with this pigmentary disorder (Le Poole et al., 2001). 
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Disease 
Vitiligo. 
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